Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Distributive Shock Treatment & Management

  • Author: Klaus-Dieter Lessnau, MD, FCCP; Chief Editor: Michael R Pinsky, MD, CM, Dr(HC), FCCP, MCCM  more...
 
Updated: Oct 08, 2015
 

Approach Considerations

The primary goals of treatment are to reverse the underlying cause of shock (eg, treat the infection by draining abscesses and debridement) and hemodynamic stabilization of the patient.

The management of patients with shock is multifactorial and guidelines are evolving.[19, 20, 21, 22, 23] Of note, the Surviving Sepsis Campaign (SSC), composed of international experts, assessed the available evidence and published consensus guidelines.[24]

Monitoring

All patients with distributive shock should be admitted to an intensive care unit (ICU). Vital signs and fluid intake and output should be measured and charted on an hourly basis. Daily weights should be obtained, and adequate intravascular access should be secured. A central venous access device should be considered if vasoactive drug support is required. Placement of pulmonary artery (PA) and arterial catheters should be considered. Most patients should have an indwelling urinary catheter.

Oxygen should be administered immediately by mask. In patients with altered mental status, respiratory distress, or severe hypotension, elective endotracheal intubation and mechanical ventilation should be considered; these avoid emergent intubation in the event of subsequent respiratory arrest. Mechanical ventilation can also aid in hemodynamic stabilization, by decreasing the demands posed by the respiratory muscles on the circulation (as much as 40% of the cardiac output during respiratory distress).

Prophylaxis

All patients should be treated prophylactically against thromboembolic disease, gastric stress ulceration, and pressure ulcers.

Next

Resuscitation

Early, efficient resuscitation is the key. The duration of hypotension before antibiotic treatment has been found to be a critical factor in determining mortality.[25] Rivers et al found a significant decrease in in-hospital mortality when patients were treated with early, goal-directed therapy.[26] This protocol-driven resuscitation strategy focused on optimizing hemodynamic parameters and reversing hypoperfusion beginning in the emergency department; these protocols have been successfully implemented not only in research centers, but also in community-based settings.[27, 28, 29, 30] .

As soon as hypoperfusion is detected, continue fluid over the first 6 hours using protocol-defined goals for central venous pressure, mean arterial pressure, urine output, and/or mixed venous oxygen saturation. If central venous oxygen saturation of more than 70% is not achieved in the first 6 hours, SSC recommendations suggest (based on clinical assessment) transfusing packed red blood cells, targeting a hematocrit at greater than or equal to 30% or treatment with dobutamine.[31, 32, 33] However, two major studies (ARISE,[34] ProCESS[35] ) have not shown improved survival with protocol-based therapy, as compared with nonprotocol "usual" therapy. Furthermore, a major study on a perioperative, cardiac output–guided hemodynamic therapy algorithm, with the use of inotropic medication for patients with major gastrointestinal surgery, also did not show increased survival.[36] The impact of these three studies on protocol-based therapy is currently controversial.

The choice of fluid for resuscitation has been a matter of ongoing debate. The SSC recommends the use of either colloids or crystalloids, finding inadequate evidence to recommend one over the other. The Saline Versus Albumin Fluid Evaluation (SAFE) trial found crystalloid and colloid to be equally safe and effective for ICU patients. In contrast to prior studies, it also found no difference or increased mortality among patients receiving albumin.[37, 38, 39, 40, 41]

A meta-analysis revealed that passive leg raising-induced changes in cardiac output (PLR-cCO) can reliably predict fluid responsiveness, regardless of ventilation mode and cardiac rhythm.[42] PLR-cCO has a significantly higher predictive value than arterial pulse pressure.

A retrospective cohort study of trauma patients who received allogeneic packed red blood cells sought to determine the association between infection or death and blood storage duration. Results showed that patients who received 7 units or more of older blood had a higher risk of complicated sepsis compared with patients who received 1 or fewer units. The effects of allogeneic blood is best reduced by avoiding unnecessary transfusions, but it may also be important to avoid transfusions of multiple units of older blood.[43]

In the Multicenter Randomized Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP) study, comparing hydroxyethyl starch (HES) to Ringer's lactate, the HES group had higher rates of renal failure and more days on renal replacement therapy. Additional investigation is required to fully appreciate the risks versus benefits of this intervention.[44, 45]

Vasoactive drugs

In patients with hypotension due to sustained septic shock in whom fluid resuscitation does not reverse hypotension, the use of systemic vasopressors is indicated to restore blood flow to pressure-dependent vascular beds (eg, the heart and brain). Either norepinephrine or dopamine should be used as first-line treatment; no evidence suggests the use of one over the other. Several vasopressor agents are available. (See Table 2, below.)

If dopamine is tried first and fails to increase mean arterial pressure to more than 60mm Hg or if excessive tachycardia or tachyarrhythmias develop, norepinephrine (Levophed) should be used. As a second-line treatment, phenylephrine (Neo-Synephrine) may be added to or substituted for dopamine. Dobutamine may be added to the therapeutic regimen when cardiac output is low, recognizing that this drug acts primarily as a positive inotropic agent and may further decrease systemic vascular resistance (SVR).

Importantly, because severe sepsis is usually associated with some degree of myocardial depression, the use of an unopposed alpha stimulant to increase vasomotor tone without a concomitant increase in inotropy decreases cardiac output. This was the universal finding when nitric oxide synthase inhibitors were used to treat the hypotension of septic shock in a large prospective, clinical trial. The doses and cardiovascular characteristics of commonly used vasoactive drugs for shock are summarized in Table 2, below.

Vasopressin

As a second-line treatment, vasopressin may be helpful to increase mean arterial pressure and SVR and may be considered in patients who are refractory to inotropic agents and have a cardiac output that is already more than 3.5 L/min/m2. Endogenous vasopressin is released from the pituitary gland as part of the physiologic response to shock, acting on V1 receptors of vascular smooth muscle to induce vasoconstriction. As shock continues, endogenous vasopressin levels may be depressed, perhaps due to depletion of the stores or impaired hypophyseal function in the setting of infection. This contributes to refractory hypotension.[46, 47, 48, 49]

In this setting of hypotension, treatment with exogenous vasopressin has a role. Vasopressin treatment carries the risk of acidosis by causing splanchnic vasodilation and resultant ischemia. Myocardial ischemia is also possible, given increased afterload and coronary vasoconstriction. Although current treatment guidelines support vasopressin’s use, a randomized trial in which vasopressin was added to ongoing norepinephrine treatment did not find a benefit to the use of vasopressin over norepinephrine, suggesting that additional investigation will be required to define vasopressin’s role.[49] In a 2012 meta-analysis, Serpa et al found that vasopressin treatment in patients with vasodilatory shock was safe and was associated with reduced mortality.[50]

Table 2. Vasoactive Drugs in Sepsis and the Usual Hemodynamic Responses (Open Table in a new window)

Drug Dose Principal Mechanism Cardiac Output Blood Pressure SVR
Inotropic agents
Dobutamine 2-20 mcg/kg/min Beta 1 ++ + +
Dopamine



(low dose)



5-10 mcg/kg/min Beta 1, dopamine ++ + +
Epinephrine (low dose) 0.06-0.20 mcg/kg/min Beta 1, beta 2 >alpha ++ + +
Inotropic agents and vasoconstrictors
Dopamine (high dose) >10 mcg/kg/min Alpha, beta 1, dopamine ++ ++ +
Epinephrine



(high dose)



0.21-0.42 mcg/kg/min Alpha >beta 1, beta 2 ++ ++ +
Norepinephrine 0.02-0.25 mcg/kg/min Alpha >beta 1, beta 2 + ++ ++
Vasoconstrictors
Phenylephrine 0.2-2.5 mcg/kg/min Alpha + ++ ++
Vasopressin 0.10-0.40 U/min V1 receptor + + ++
Vasodilators
Dopamine



(very low dose)



1-4 mcg/kg/min Dopamine +/- +/- -
Milrinone 0.4-0.6 mcg/kg/min after loading dose; 50 mcg/kg bolus over 5 min Phosphodiesterase inhibitor + +/- -
Alpha and beta refer to agonist activity at these adrenergic receptor sites.



Beta 1-adrenergic effects are inotropic and increase contractility.



Beta 2-adrenergic effects are chronotropic.[51]



Previous
Next

Antimicrobial Treatment

In all patients with suspected sepsis, blood and urine cultures should be collected prior to empiric antibiotic therapy, provided that this does not cause a significant delay in treatment. At least 2 blood cultures should be collected and should be drawn percutaneously, as well as from any vascular access site. Cultures such as respiratory tract secretions and cerebrospinal fluid should be collected if infection at these sites is suspected clinically.

Patients who receive prompt effective antimicrobial therapy are more likely to survive than are patients whose antibiotic therapy is delayed; measurable increases in mortality occur for each hour’s delay in antibiotic treatment. Because initial therapy must be empiric, antimicrobial coverage should be broad and should have good penetration to all suspected sites of infection.

The choice of agent should be guided by history, suspected site of infection, comorbid diseases, and pathogen susceptibility patterns in the hospital and community. Avoid antibiotics recently received by the patient. Treatment of fungal infection should be considered and selection of an antifungal agent should be guided by the local prevalence of Candida species. Recommended empiric antibiotic regimens based on the suspected site are outlined in Table 3, below.

Antimicrobial regimens should be tailored once the causative pathogen and its susceptibility are identified because narrow-spectrum treatment decreases the risk of superinfection with resistant organisms. The duration of therapy varies based on clinical context, but the SSC guidelines suggest that the typical duration will be 7-10 days, with adjustments made for factors such as underlying immune status and undrainable foci of infection.

Consider the removal of any devices, such as intravenous or urinary catheters and prostheses. Surgical drainage or debridement should be performed promptly, when appropriate (eg, intra-abdominal abscess, necrotizing fasciitis).

Table 3. Empiric Antimicrobial Therapy in Septic Shock Based on Suspected Site of Infection (Open Table in a new window)

Suspected Source Recommended Antibiotic Therapy Alternative Therapy
No source evident in a healthy host Third-generation cephalosporin, eg, ceftriaxone 2 g IV q12h, ceftizoxime, ceftazidime Nafcillin and aminoglycoside, imipenem, piperacillin/tazobactam
No source evident in an immunocompromised host Ceftazidime 2 g IV q8h plus aminoglycoside Imipenem or piperacillin/tazobactam plus aminoglycoside
No source evident in a user of intravenous drugs Nafcillin 2 g IV q4h plus aminoglycoside Vancomycin plus aminoglycoside, ceftazidime, imipenem, or piperacillin/tazobactam
Bacterial pneumonia, community acquired Ceftriaxone 2 g IV q12-24 h plus macrolide Levofloxacin 750mg IV q24h, cotrimoxazole or imipenem plus macrolide
Bacterial pneumonia, hospital acquired Piperacillin/tazobactam 4.5 g IV q6h plus aminoglycoside, plus levofloxacin 750 mg IV q24h Imipenem plus aminoglycoside, plus macrolide
Urinary tract infection Ampicillin 2 g IV q4h plus aminoglycoside Fluoroquinolone or third-generation cephalosporin plus aminoglycoside
Mixed aerobic and anaerobic abdominal sepsis, aspiration pneumonia, pelvic infection, and necrotizing cellulitis Third-generation cephalosporin or ampicillin 2 g IV q4h plus aminoglycoside plus clindamycin 600 mg IV q8h or metronidazole 500 mg IV q6h Fluoroquinolone plus clindamycin, imipenem, piperacillin/tazobactam
Meningitis Ceftriaxone 2 g IV q12h plus vancomycin Meropenem plus vancomycin, chloramphenicol plus cotrimoxazole plus vancomycin
Cellulitis/erysipelas Nafcillin 2 g IV q4h Cefazolin, vancomycin, clindamycin
Toxic shock syndrome (TSS) or streptococcal necrotizing fasciitis Clindamycin 600 mg IV q8h Cephalosporin, vancomycin, nafcillin
Previous
Next

Preventing Microvascular Thrombosis

This has become a strategy for preventing sepsis-related organ failure. Disseminated intravascular coagulation (DIC) is a critical factor in driving the progression of sepsis. Activated protein C (APC), an endogenous protein that decreases thrombosis and inflammation, has been used for septic shock but was withdrawn by the company for lack of significant efficiency.[9, 52, 53, 54, 55, 56, 57, 58]

Previous
Next

Corticosteroids

The role of corticosteroids as an adjunct treatment for septic shock has been an area of debate. The role of corticosteroids in sepsis is a matter of debate, with positive and negative studies in the literature. Low-dose hydrocortisone and fludrocortisone have been used for patients with severe sepsis and adrenal insufficiency who remain hypotensive after fluid resuscitation and pressors and were traditionally thought to reduce mortality in this subgroup.[59, 60, 61, 62]

In contrast to prior studies, however, a multi-site, double-blind, placebo-controlled trial found that low-dose hydrocortisone did not affect mortality at 28 days, although patients receiving hydrocortisone had an earlier reversal of shock. Also in contrast to prior work, this study did not find that a corticotropin stimulation test predicted response to hydrocortisone. Additional studies are required to address these discrepancies.

The SSC recommendations acknowledge this controversy and support giving hydrocortisone only to hypotensive patients poorly responsive to fluid resuscitation and vasopressors. Given findings that suggest the adrenocorticotropic hormone (ACTH) stimulation test does not predict response to steroids, this test is no longer recommended. Hydrocortisone, rather than dexamethasone or fludrocortisone, is the steroid of choice; it is not yet clear if adding fludrocortisone to hydrocortisone provides added benefit.[63]

Previous
Next

Glucose

Protocol-driven management of glucose (target < 150-180 mg/dL) is recommended, with monitoring every 1-2 hours until glucose levels are stable and then every 4 hours thereafter. This SSC recommendation is based on studies that found decreased mortality, length of stay, and complications such as renal impairment. Of note, intensive glucose management has been associated with higher rates of severe hypoglycemic events and, in some studies, has not been associated with improved mortality.

Previous
Next

NO Scavenger

Pyridoxalated hemoglobin polyoxyethylene (PHP) is a hemoglobin-based nitric oxide (NO) scavenger that has been shown to increase systemic blood pressure and reduce vasopressor and ventilation needs in patients with NO-induced shock without adversely affecting cardiac output, organ function, or survival. The results of its use in distributive shock in a multicenter, randomized, placebo-controlled, phase II study were promising, but further studies are needed to provide a definitive answer.[64]

Previous
Next

Treatment of Anaphylaxis

If anaphylaxis is suspected, 0.2-0.5 mL subcutaneous of 1:1000 epinephrine should be administered immediately, with repeated doses every 20 minutes as needed. Epinephrine can be administered by continuous infusion of 30-60 mL/h of 1:10,000 dilution in severe reactions. Diphenhydramine 50-80 mg intramuscular or intravenous may be administered for urticaria or angioedema. Inhaled bronchodilators or intravenous steroids can be administered for bronchospasm.

Previous
Next

Surgical Control of Shock Sources

In addition to prompt fluid resuscitation, hemodynamic support with vasoactive drugs, and prompt establishment of broad-spectrum antibiotic coverage, source control is essential to effective treatment of shock. Early efforts should be made to define sources in need of surgical intervention, such as necrotizing fasciitis, cholangitis, abscess, intestinal ischemia, or an infected device. The least-invasive means of intervention should be used.[65]

Multiple surgical modalities for source control are indicated, including the following:

  • Removal of infected catheters, infected prosthesis, and foreign bodies
  • Drainage (operative, endoscopic, percutaneous) of intra-abdominal abscess, postoperative collections, soft-tissue abscess, and gallbladder sludge
  • Debridement of devitalized (traumatic or infected) tissue, pancreatic necrosis, and soft-tissue infections
  • Operative resection of inflamed, infarcted, ischemic, and perforated hollow viscus
  • Amputation of gangrenous extremities
Previous
Next

Diet

Once the initial phase of resuscitation is complete, promptly institute nutritional support, usually within 24 hours. This is especially important in malnourished patients (with temporal muscle atrophy).

In patients who are intubated or obtunded, tube feedings should be initiated through a soft nasogastric or orogastric feeding tube at a slow rate and increased over 12-24 hours to the target rate.

If patients cannot be fed enterally, parenteral nutrition may be instituted until enteral feeding becomes possible. Enteral feeding is preferred because it is less expensive and is associated with lower rates of nosocomial infection than total parenteral nutrition.

Previous
Next

Inpatient Care

Transfer of a patient admitted with distributive shock from the ICU to a stepdown or ward unit is highly individualized. The patient's condition and prognosis must be assessed and matched to the level of care in the receiving unit.

Generally, patients can be considered for transfer when they are hemodynamically stable without vasoactive drugs, when ventilation and oxygenation is stable on supplemental oxygen delivered by nasal cannula, when life-threatening metabolic derangements are absent, and when the patients no longer require the high nursing and respiratory therapy ratios characteristic of ICU care (ie, for frequent suctioning).

Previous
Next

Transfer

Transferring a patient with distributive shock from one hospital to another exposes the patient to risk and should be undertaken only when the receiving institution can offer the patient care that is not available at the transferring hospital.

In general, institutions that care for critically ill patients need an appropriately staffed ICU that is capable of delivering and monitoring mechanical ventilation and invasive monitoring devices such as pulmonary artery (PA) catheters and arterial lines.

Modern surgical facilities, a radiology department equipped with ultrasonographic and CT scanners, dialysis equipment, and medical specialists to deliver these specialized types of care and procedures are also a minimum requirement. Lack of any one of these resources may necessitate transfer.

Under certain circumstances, patients may also benefit from transfer to units that specialize in care for trauma, burns, or cardiac or neurosurgical problems or to units where organ transplantation is available.

Previous
Next

Consultations

Intensivist

Consultation with or primary management by a board-certified medical or surgical intensivist is indicated for all patients with distributive shock.

Experienced intensivists may be trained in pulmonary/critical care medicine, cardiology, surgery, or anesthesiology. The choice of consultant may depend on patient characteristics and the availability of local subspecialists.

Infectious disease specialist

Consultation with a subspecialist in infectious disease is appropriate whenever sepsis is suspected as a cause of distributive shock.

This is particularly true when the locus of infection is unknown or unique patient characteristics (such as travel history or occupation) raise the possibility of an unusual or rare infectious process.

Surgeon

Consultation with a surgeon should always be obtained when an abdominal source of sepsis is suspected. Other indications for consultation with a surgeon include, but are not limited to, necrotizing fasciitis, soft tissue abscess, empyema (thoracic surgeon), or brain abscess (neurosurgeon).

Previous
 
 
Contributor Information and Disclosures
Author

Klaus-Dieter Lessnau, MD, FCCP Clinical Associate Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory; Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital

Klaus-Dieter Lessnau, MD, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, American Thoracic Society, Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Ruben Peralta, MD, FACS Professor of Surgery, Anesthesia and Emergency Medicine, Senior Medical Advisor, Board of Directors, Program Chief of Trauma, Emergency and Critical Care, Consulting Staff, Professor Juan Bosch Trauma Hospital, Dominican Republic

Ruben Peralta, MD, FACS is a member of the following medical societies: American Association of Blood Banks, American College of Surgeons, American Medical Association, Association for Academic Surgery, Massachusetts Medical Society, Society of Critical Care Medicine, Society of Laparoendoscopic Surgeons, Eastern Association for the Surgery of Trauma, American College of Healthcare Executives

Disclosure: Nothing to disclose.

Chief Editor

Michael R Pinsky, MD, CM, Dr(HC), FCCP, MCCM Professor of Critical Care Medicine, Bioengineering, Cardiovascular Disease, Clinical and Translational Science and Anesthesiology, Vice-Chair of Academic Affairs, Department of Critical Care Medicine, University of Pittsburgh Medical Center, University of Pittsburgh School of Medicine

Michael R Pinsky, MD, CM, Dr(HC), FCCP, MCCM is a member of the following medical societies: American College of Chest Physicians, Association of University Anesthetists, European Society of Intensive Care Medicine, American College of Critical Care Medicine, American Heart Association, American Thoracic Society, Shock Society, Society of Critical Care Medicine

Disclosure: Received income in an amount equal to or greater than $250 from: Masimo<br/>Received honoraria from LiDCO Ltd for consulting; Received intellectual property rights from iNTELOMED for board membership; Received honoraria from Edwards Lifesciences for consulting; Received honoraria from Masimo, Inc for board membership.

Additional Contributors

Lalit K Kanaparthi, MD Attending Physician, North Florida Lung Associates

Lalit K Kanaparthi, MD is a member of the following medical societies: American College of Chest Physicians, American Medical Association, American Thoracic Society

Disclosure: Nothing to disclose.

Acknowledgements

Cory Franklin, MD Professor, Department of Medicine, Rosalind Franklin University of Medicine and Science; Director, Division of Critical Care Medicine, Cook County Hospital

Cory Franklin, MD is a member of the following medical societies: New York Academy of Sciences and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Sarah C Langenfeld, MD Assistant Professor, Department of Psychiatry, University of Massachusetts Medical School; Attending Psychiatrist, Community HealthLink

Sarah Langenfeld, MD is a member of the following medical societies: American Medical Association, American Psychiatric Association, and Massachusetts Medical Society

Disclosure: Nothing to disclose.

Scott P Neeley, MD Medical Director, Intensive Care Unit, St Alexius Medical Center

Scott P Neeley, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physician Executives, American College of Physicians, American Thoracic Society, Phi Beta Kappa, and Sigma Xi

Disclosure: Nothing to disclose.

Daniel R Ouellette, MD, FCCP Associate Professor of Medicine, Wayne State University School of Medicine; Consulting Staff, Pulmonary Disease and Critical Care Medicine Service, Henry Ford Health System

Daniel R Ouellette, MD, FCCP is a member of the following medical societies: American College of Chest Physicians and American Thoracic Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003 Apr. 31(4):1250-6. [Medline].

  2. Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost. 1998. 24(1):33-44. [Medline].

  3. Levi M. Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient. J Crit Care. 2001 Dec. 16(4):167-77. [Medline].

  4. Friedman, Gilberto MD; Silva, Eliezer MD; Vincent, Jean-Louis MD, PhD, FCCM. Has the mortality of septic shock changed with time?. Critical Care Medicine. December 1998. 26(12):2078-2086. [Full Text].

  5. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001 Jul. 29(7):1303-10. [Medline].

  6. Rubulotta FM, Ramsay G, Parker MM, Dellinger RP, Levy MM, Poeze M. An international survey: Public awareness and perception of sepsis. Crit Care Med. 2009 Jan. 37(1):167-70. [Medline].

  7. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992 Jun. 101(6):1644-55. [Medline].

  8. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993 May 20. 328(20):1471-7. [Medline].

  9. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001 Mar 8. 344(10):699-709. [Medline].

  10. Bastani A, Galens S, Rocchini A, Walch R, Shaqiri B, Palomba K, et al. ED identification of patients with severe sepsis/septic shock decreases mortality in a community hospital. Am J Emerg Med. 2011 Dec 26. [Medline].

  11. Girard TD, Jackson JC, Pandharipande PP, et al. Delirium as a predictor of long-term cognitive impairment in survivors of critical illness. Crit Care Med. 2010 Jul. 38(7):1513-20. [Medline].

  12. Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004 Apr 14. 291(14):1753-62. [Medline].

  13. Desai SV, Law TJ, Needham DM. Long-term complications of critical care. Crit Care Med. 2011 Feb. 39(2):371-9. [Medline].

  14. Marik PE, Kiminyo K, Zaloga GP. Adrenal insufficiency in critically ill patients with human immunodeficiency virus. Crit Care Med. 2002 Jun. 30(6):1267-73. [Medline].

  15. Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med. 2003 Jan 2. 348(1):5-14. [Medline].

  16. Shah MR, Hasselblad V, Stevenson LW, Binanay C, O'Connor CM, Sopko G. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. JAMA. 2005 Oct 5. 294(13):1664-70. [Medline].

  17. Ince C. The microcirculation is the motor of sepsis. Crit Care. 2005. 9 Suppl 4:S13-9.

  18. Elbers PW, Ince C. Mechanisms of critical illness--classifying microcirculatory flow abnormalities in distributive shock. Crit Care. 2006. 10(4):221. [Medline]. [Full Text].

  19. Micek ST, Roubinian N, Heuring T, et al. Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med. 2006 Nov. 34(11):2707-13. [Medline].

  20. Nguyen HB, Corbett SW, Steele R, et al. Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality. Crit Care Med. 2007 Apr. 35(4):1105-12. [Medline].

  21. Sebat F, Johnson D, Musthafa AA, et al. A multidisciplinary community hospital program for early and rapid resuscitation of shock in nontrauma patients. Chest. 2005 May. 127(5):1729-43. [Medline].

  22. Trzeciak S, Dellinger RP, Abate NL, et al. Translating research to clinical practice: a 1-year experience with implementing early goal-directed therapy for septic shock in the emergency department. Chest. 2006 Feb. 129(2):225-32. [Medline].

  23. Lagu T, Rothberg MB, Nathanson BH, Pekow PS, Steingrub JS, Lindenauer PK. Variation in the care of septic shock: The impact of patient and hospital characteristics. J Crit Care. 2012 Jan 31. [Medline].

  24. Zambon M, Ceola M, Almeida-de-Castro R, Gullo A, Vincent JL. Implementation of the Surviving Sepsis Campaign guidelines for severe sepsis and septic shock: we could go faster. J Crit Care. 2008 Dec. 23(4):455-60. [Medline].

  25. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006 Jun. 34(6):1589-96. [Medline].

  26. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 Nov 8. 345(19):1368-77. [Medline].

  27. Jones AE, Focht A, Horton JM, Kline JA. Prospective external validation of the clinical effectiveness of an emergency department-based early goal-directed therapy protocol for severe sepsis and septic shock. Chest. 2007 Aug. 132(2):425-32. [Medline].

  28. Kortgen A, Niederprum P, Bauer M. Implementation of an evidence-based "standard operating procedure" and outcome in septic shock. Crit Care Med. 2006 Apr. 34(4):943-9. [Medline].

  29. McIntyre LA, Fergusson D, Cook DJ, et al. Resuscitating patients with early severe sepsis: a Canadian multicentre observational study. Can J Anaesth. 2007 Oct. 54(10):790-8. [Medline].

  30. McIntyre LA, Hebert PC, Fergusson D, Cook DJ, Aziz A. A survey of Canadian intensivists' resuscitation practices in early septic shock. Crit Care. 2007. 11(4):R74. [Medline].

  31. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008 Jan. 34(1):17-60. [Medline].

  32. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008 Jan. 36(1):296-327. [Medline].

  33. Gunn SR, Fink MP, Wallace B. Equipment review: the success of early goal-directed therapy for septic shock prompts evaluation of current approaches for monitoring the adequacy of resuscitation. Crit Care. 2005 Aug. 9(4):349-59. [Medline].

  34. ARISE Investigators, ANZICS Clinical Trials Group, Peake SL, Delaney A, Bailey M, Bellomo R, et al. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014 Oct 16. 371 (16):1496-506. [Medline].

  35. ProCESS Investigators, Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014 May 1. 370 (18):1683-93. [Medline].

  36. Pearse RM, Harrison DA, MacDonald N, Gillies MA, Blunt M, Ackland G, et al. Effect of a perioperative, cardiac output-guided hemodynamic therapy algorithm on outcomes following major gastrointestinal surgery: a randomized clinical trial and systematic review. JAMA. 2014 Jun 4. 311 (21):2181-90. [Medline].

  37. Dubois MJ, Orellana-Jimenez C, Melot C, et al. Albumin administration improves organ function in critically ill hypoalbuminemic patients: A prospective, randomized, controlled, pilot study. Crit Care Med. 2006 Oct. 34(10):2536-40. [Medline].

  38. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004 May 27. 350(22):2247-56. [Medline].

  39. Finfer S, Bellomo R, McEvoy S, Lo SK, Myburgh J, Neal B, et al. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ. 2006 Nov 18. 333(7577):1044. [Medline].

  40. Finfer S, Myburgh J, Bellomo R. Albumin supplementation and organ function. Crit Care Med. 2007 Mar. 35(3):987-8. [Medline].

  41. Myburgh J, Cooper DJ, Finfer S, et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med. 2007 Aug 30. 357(9):874-84. [Medline].

  42. Cavallaro F, Sandroni C, Marano C, La Torre G, Mannocci A, De Waure C, et al. Diagnostic accuracy of passive leg raising for prediction of fluid responsiveness in adults: systematic review and meta-analysis of clinical studies. Intensive Care Med. 2010 Sep. 36(9):1475-83. [Medline].

  43. Hassan M, Pham TN, Cuschieri J, Warner KJ, Nester T, Maier RV, et al. The association between the transfusion of older blood and outcomes after trauma. Shock. 2011 Jan. 35(1):3-8. [Medline].

  44. Zander R, Boldt J, Engelmann L, Mertzlufft F, Sirtl C, Stuttmann R. [The design of the VISEP trial. Critical appraisal]. Anaesthesist. 2007 Jan. 56(1):71-7. [Medline].

  45. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008 Jan 10. 358(2):125-39. [Medline].

  46. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest. 2001 Sep. 120(3):989-1002. [Medline].

  47. Landry DW, Oliver JA. Vasopressin and relativity: on the matter of deficiency and sensitivity. Crit Care Med. 2006 Apr. 34(4):1275-7. [Medline].

  48. Lauzier F, Levy B, Lamarre P, Lesur O. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med. 2006 Nov. 32(11):1782-9. [Medline].

  49. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008 Feb 28. 358(9):877-87. [Medline].

  50. Serpa Neto A, Nassar Junior AP, Cardoso SO, Manettta JA, Pereira VG, Esposito DC, et al. Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials. Crit Care. 2012 Aug 14. 16(4):R154. [Medline].

  51. Holmes CL. Vasoactive drugs in the intensive care unit. Curr Opin Crit Care. 2005 Oct. 11(5):413-7. [Medline].

  52. Kinasewitz GT, Zein JG, Lee GL, et al. Prognostic value of a simple evolving disseminated intravascular coagulation score in patients with severe sepsis. Crit Care Med. 2005 Oct. 33(10):2214-21.

  53. Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest. 2005 Oct. 128(4):2864-75. [Medline].

  54. Hoffmann JN, Vollmar B, Laschke MW, et al. Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition. Crit Care. 2005. 9 Suppl 4:S33-7.

  55. Mackenzie AF. Activated protein C: do more survive?. Intensive Care Med. 2005 Dec. 31(12):1624-6.

  56. O'Brien LA, Gupta A, Grinnell BW. Activated protein C and sepsis. Front Biosci. 2006. 11:676-98. [Medline].

  57. Parrillo JE. Severe sepsis and therapy with activated protein C. N Engl J Med. 2005 Sep 29. 353(13):1398-400. [Medline].

  58. Wiedermann CJ, Kaneider NC. A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis. BMC Emerg Med. 2005 Oct 14. 5:7. [Medline].

  59. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ. 2004 Aug 28. 329(7464):480. [Medline]. [Full Text].

  60. Raurich JM, Llompart-Pou JA, Ibanez J, et al. Low-dose steroid therapy does not affect hemodynamic response in septic shock patients. J Crit Care. 2007 Dec. 22(4):324-9. [Medline].

  61. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008 Jan 10. 358(2):111-24. [Medline].

  62. Bruno JJ, Dee BM, Anderegg BA, Hernandez M, Pravinkumar SE. US practitioner opinions and prescribing practices regarding corticosteroid therapy for severe sepsis and septic shock. J Crit Care. 2012 Feb 14. [Medline].

  63. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002 Aug 21. 288(7):862-71. [Medline].

  64. Kinasewitz GT, Privalle CT, Imm A, et al. Multicenter, randomized, placebo-controlled study of the nitric oxide scavenger pyridoxalated hemoglobin polyoxyethylene in distributive shock. Crit Care Med. 2008 Jul. 36(7):1999-2007. [Medline].

  65. Jimenez MF, Marshall JC. Source control in the management of sepsis. Intensive Care Med. 2001. 27 Suppl 1:S49-62. [Medline].

  66. Vincent JL, Ince C, Bakker J. Clinical review: Circulatory shock--an update: a tribute to Professor Max Harry Weil. Crit Care. 2012 Nov 20. 16 (6):239. [Medline].

 
Previous
Next
 
An 8-year-old boy developed septic shock secondary to Blastomycosis pneumonia. Fungal infections are a rare cause of septic shock.
A 28-year-old woman who was a previous intravenous drug user (human immunodeficiency virus [HIV] status: negative) developed septic shock secondary to bilateral pneumococcal pneumonia.
Microcirculatory abnormalities in distributive shock. Each image represents a venule (large, curved tube) and 2 capillaries (smaller tubes) and demonstrates the 2 main capillary flow patterns found in each class of microcirculatory abnormality, as they occur in distributive shock. This classification system was introduced by Elbers and Ince. Elbers P, Ince C. Bench-to-bedside review: mechanisms of critical illness—classifying microcirculatory flow abnormalities in distributive shock. Crit Care. July 19 2006;10(4):221.
Table 1. Pulmonary Artery Catheter Findings in Common Shock States
Diagnosis Pulmonary Capillary Wedge Pressure Cardiac Output
Cardiogenic shock* Increased Decreased
Extracardiac obstructive shock



1. Pericardial tamponade†



2. Pulmonary embolism



Increased



Normal or decreased



Decreased



Decreased



Hypovolemic shock Decreased Decreased
Distributive shock



1. Septic shock



2. Anaphylactic shock



Normal or decreased



Normal or decreased



Increased or normal



Increased or normal



*In cardiogenic shock due to a mechanical defect, such as mitral regurgitation, forward cardiac output is reduced, although the measured cardiac output may be unreliable. Large V waves are commonly observed in the pulmonary capillary wedge tracing in mitral regurgitation.



†The hallmark finding is equalization of right atrial mean, right ventricular end-diastolic, pulmonary artery (PA) end-diastolic, and pulmonary capillary wedge pressures.



Table 2. Vasoactive Drugs in Sepsis and the Usual Hemodynamic Responses
Drug Dose Principal Mechanism Cardiac Output Blood Pressure SVR
Inotropic agents
Dobutamine 2-20 mcg/kg/min Beta 1 ++ + +
Dopamine



(low dose)



5-10 mcg/kg/min Beta 1, dopamine ++ + +
Epinephrine (low dose) 0.06-0.20 mcg/kg/min Beta 1, beta 2 >alpha ++ + +
Inotropic agents and vasoconstrictors
Dopamine (high dose) >10 mcg/kg/min Alpha, beta 1, dopamine ++ ++ +
Epinephrine



(high dose)



0.21-0.42 mcg/kg/min Alpha >beta 1, beta 2 ++ ++ +
Norepinephrine 0.02-0.25 mcg/kg/min Alpha >beta 1, beta 2 + ++ ++
Vasoconstrictors
Phenylephrine 0.2-2.5 mcg/kg/min Alpha + ++ ++
Vasopressin 0.10-0.40 U/min V1 receptor + + ++
Vasodilators
Dopamine



(very low dose)



1-4 mcg/kg/min Dopamine +/- +/- -
Milrinone 0.4-0.6 mcg/kg/min after loading dose; 50 mcg/kg bolus over 5 min Phosphodiesterase inhibitor + +/- -
Alpha and beta refer to agonist activity at these adrenergic receptor sites.



Beta 1-adrenergic effects are inotropic and increase contractility.



Beta 2-adrenergic effects are chronotropic.[51]



Table 3. Empiric Antimicrobial Therapy in Septic Shock Based on Suspected Site of Infection
Suspected Source Recommended Antibiotic Therapy Alternative Therapy
No source evident in a healthy host Third-generation cephalosporin, eg, ceftriaxone 2 g IV q12h, ceftizoxime, ceftazidime Nafcillin and aminoglycoside, imipenem, piperacillin/tazobactam
No source evident in an immunocompromised host Ceftazidime 2 g IV q8h plus aminoglycoside Imipenem or piperacillin/tazobactam plus aminoglycoside
No source evident in a user of intravenous drugs Nafcillin 2 g IV q4h plus aminoglycoside Vancomycin plus aminoglycoside, ceftazidime, imipenem, or piperacillin/tazobactam
Bacterial pneumonia, community acquired Ceftriaxone 2 g IV q12-24 h plus macrolide Levofloxacin 750mg IV q24h, cotrimoxazole or imipenem plus macrolide
Bacterial pneumonia, hospital acquired Piperacillin/tazobactam 4.5 g IV q6h plus aminoglycoside, plus levofloxacin 750 mg IV q24h Imipenem plus aminoglycoside, plus macrolide
Urinary tract infection Ampicillin 2 g IV q4h plus aminoglycoside Fluoroquinolone or third-generation cephalosporin plus aminoglycoside
Mixed aerobic and anaerobic abdominal sepsis, aspiration pneumonia, pelvic infection, and necrotizing cellulitis Third-generation cephalosporin or ampicillin 2 g IV q4h plus aminoglycoside plus clindamycin 600 mg IV q8h or metronidazole 500 mg IV q6h Fluoroquinolone plus clindamycin, imipenem, piperacillin/tazobactam
Meningitis Ceftriaxone 2 g IV q12h plus vancomycin Meropenem plus vancomycin, chloramphenicol plus cotrimoxazole plus vancomycin
Cellulitis/erysipelas Nafcillin 2 g IV q4h Cefazolin, vancomycin, clindamycin
Toxic shock syndrome (TSS) or streptococcal necrotizing fasciitis Clindamycin 600 mg IV q8h Cephalosporin, vancomycin, nafcillin
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.